NASDAQ:ALLR
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc.'s revenue was $320,000 in fiscal 2025. Free cash flow was −$14.8M, −4633.8% of revenue.Summary generated from Allarity Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$320,000
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−3939.1%
Net margin−3509.7%
ROICn/a
Return on equity−103.8%
Debt / equityn/a
Free cash flow−$14.8M
FCF margin−4633.8%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | 0 | 0 |
| Operating income | −27 | −34 | −17 | −27 | −13 |
| Net income | −27 | −16 | −12 | −25 | −11 |
| Free cash flow | n/a | −17 | −13 | −18 | −15 |
Recent filings
- 4Insider transaction report
Oct 9, 2026 - 8-KOther events
Oct 1, 2026 - 8-KOther events
Sep 29, 2026 - 8-KOther events
Sep 16, 2026 - 8-KOther events
Sep 14, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of a shareholder vote
Jul 1, 2026